Physician profile
Faiz Anwer
NPI 1356543169
$19,957.22
in general payments reported to CMS, 2019-2025
14 companies · $13K in 2025
The $13K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2023: $6,006 · 2024: $377 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $1,237 · Education: $198 · Grant: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,220.00 |
| Food and Beverage | $1,236.88 |
| Education | $198.00 |
| Grant | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $15,330.54 | 2023-2025 | Abecma |
| Kite Pharma, INC. | $3,190.00 | 2025 | |
| Beigene USA, INC. | $289.17 | 2023-2024 | Brukinsa |
| Janssen Biotech, INC. | $244.85 | 2025 | Carvykti, Talvey, Tecvayli |
| Pharmacosmos Therapeutics INC. | $176.82 | 2024 | Monoferric |
| Regeneron Healthcare Solutions, INC. | $144.37 | 2025 | Libtayo |
| Celgene Corporation | $115.85 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.49 | 2019 | |
| Glaxosmithkline, LLC. | $101.20 | 2025 | Ojjaara |
| Seagen INC. | $99.00 | 2025 | |
| Genzyme Corporation | $75.00 | 2023 | |
| Pfizer INC. | $60.67 | 2024 | |
| Legend Biotech USA INC. | $18.26 | 2025 | Carvykti |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faiz Anwer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.